Feasibility study of monitoring direct oral anticoagulants in geriatric patients with atrial fibrillation using capillary blood

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038235

Enrollment

Registered

2025-10-28

Start date

2026-01-28

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric patients with atrial fibrillation and polypharmacy

Interventions

Group 1: Intervention study: Lancet prick in the fingertip or alternatively to the earlobe and capillary blood sampling with a certified medical device sampler (Mitra®, Trajan Scientific Pty Ltd., Au

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Diagnosis of atrial fibrillation 2) Polypharmacy (5 or more different, systemically effective, prescribed medications) 3) Use of apixaban, rivaroxaban, dabigatran or edoxaban for at least 7 days 4) Written informed consent

Exclusion criteria

Exclusion criteria: Palliative or pre-terminal situation

Design outcomes

Primary

Measure	Time frame
Feasibility and practicability of monitoring of blood-levels in community pharmacies	—

Secondary

Measure	Time frame
- Pre-post comparison of DOAK drug concentrations in capillary blood - Evaluation of the effect on patient compliance - Identification of risk parameters for which monitoring is advisable - Assessment of influencing factors (age, kidney function, co-medication)	—

Countries

Germany

Contacts

Public ContactGeorg Hempel

Institut für Pharmazeutische und Medizinische Chemie – Klinische Pharmazie – der Universität Münster

hempege@uni-muenster.de+49 (0) 251-83-33334

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026